 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
–Induced Fibronectin Matrix Deposition by Upregulating Active 
51 Integrin in Human Mesangial Cells
Cell and Molecular Biology Section, Division of Biomedical Sciences, Imperial College School of Medicine, London, United Kingdom.
Correspondence to Dr. Roger M. Mason, Cell and Molecular Biology Section, Division of Biomedical Sciences, Imperial College School of Medicine, Sir Alexander Fleming Building, South Kensington, London SW7 2AZ, UK. Phone: +44-20-7594-43019; Fax: 44-20-7594-3015;
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
(TGF-) by high glucose. TGF- induces its downstream mediator connective tissue growth factor (CTGF), which stimulates fibronectin matrix synthesis, a process that requires the presence of 
51 integrin. Although TGF- has been shown to upregulate 51 integrin expression in human mesangial cells (HMC), little is known about the effect of CTGF on levels of this receptor. This study tested whether CTGF modulates 51 expression by HMC in culture and whether changes induced by TGF- are mediated through the induction of CTGF. FACS analysis showed that both TGF- and CTGF significantly increased cell-surface 51 levels compared with basal conditions. RT-PCR indicated that the changes were at the level of transcription. Treatment of cells with TGF- and antisense CTGF oligonucleotides significantly reduced the TGF-–induced increases in 51 levels. CTGF and TGF- also significantly increased levels of ligand-occupied cell-surface 1 integrins and cell adhesion to fibronectin, the main 51 substrate. Antisense CTGF significantly reduced the number of adherent cells from TGF-–stimulated cultures. Finally, 51 blocking antibodies inhibited HMC fibronectin matrix deposition, confirming the importance of this receptor for this process. Taken together, these data provide evidence that CTGF controls 51 expression by HMC in vitro. Alterations in 51 levels induced by TGF- are mediated at least in part through the induction of CTGF, and specific targeting of either 51 or CTGF could be useful in controlling excessive fibronectin matrix production in DN. E-mail roger.mason@ic.ac.uk |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
(TGF-) (3) and connective tissue growth factor (CTGF) (4–6). The level of both factors increase in the glomerulus in DN (3,6).
Connective tissue growth factor (CTGF) is a 36- to 38-kD cysteine-rich secreted protein (7). CTGF is encoded by an inducible immediate early gene and is one of six distinct members of the CCN family (8). The CTGF gene contains a novel TGF- response element in its promoter region (9) and is thought to be a downstream mediator of the some of the effects of TGF- (10). Several studies support this view (11–14), but CTGF is also induced by a variety of other factors such as thrombin and VEGF (15,16).
CTGF is thought to drive glomerulosclerosis and tubulointerstitial fibrosis in renal diseases (4). CTGF levels are elevated in different renal fibrotic disorders where excessive extracellular matrix formation is observed (11,17–19) and the growth factor induces matrix protein synthesis in mesangial cells in vitro (5,6,11,19).
One of the key extracellular matrix proteins secreted by human mesangial cells (HMC) is fibronectin. Levels of fibronectin are elevated in DN (20), and fibronectin secretion by HMC is increased when cultured under high glucose conditions (21–23). Fibronectin is assembled into an insoluble matrix outside the cell, and distinct regions of the molecule are required for matrix assembly (24). One of the most important regions in the fibronectin monomer for this is the cell-binding domain that incorporates the ninth and tenth type III repeats, which contain the synergy sites and RGD integrin-binding consensus respectively (24). The predominant integrin receptor that binds fibronectin and is intimately involved in matrix assembly is the 51 heterodimer. The importance of this receptor for fibronectin matrix assembly has been shown previously using monoclonal antibodies to block its function (25,26).
Levels of the 51 fibronectin receptor correlate directly with the degree of fibronectin matrix accumulation in renal disease (27,28), and it is known that the profibrotic factor TGF- upregulates receptor expression in different cell types (29,30), including rat mesangial cells and glomeruli (27,31). Little is known about the effect of CTGF on 51 levels, but it has been shown to upregulate 5 integrin transcripts in NRK fibroblasts (14). However, in view of the increased levels of CTGF in the diabetic glomerulus and its stimulatory effect on fibronectin synthesis by mesangial cells (6), we hypothesized that the factor may play a key role in promoting excessive deposition of fibronectin around mesangial cells by upregulating the expression of their fibronectin receptors. We report experiments below showing that this is the case and that similar effects induced by TGF-1 are in fact mediated by CTGF.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-actin were from Sigma (Poole, UK). The antibody to cellular (EDA+) fibronectin (MAS 521) was from Harlan Sera-Lab, Loughborough, UK. The BIIG2 hybridoma developed by Dr. Caroline H. Damsky was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA. The 12G10 1 antibody was a kind gift from Professor Martin Humphries, of the Wellcome Trust Center for Cell-Matrix Research, University of Manchester, UK. Recombinant CTGF, TGF-, and phosphothioate antisense CTGF and control oligonucleotides were obtained as described previously (6). Phosphothioate antisense (TGG GCA GAC GAA CG) and control oligonucleotides (ACC GAC CGA CGT GT) directed to CTGF were designed and manufactured by Biognostik GmbH (Göttingen, Germany), who own the intellectual property rights to the sequences (6). Monoclonal antibodies MAB1969 and MAB 1999 were from Chemicon International, Ltd, Harrow, UK. All other reagents were purchased from Sigma except where stated otherwise.
Cell Culture Conditions
HMC were routinely cultured and maintained as described previously (32). Cells between passage 6 to 10 were used for experiments.
Measurement of Fibronectin Deposited as Insoluble Matrix by HMC in Culture
HMC were maintained in RPMI 1640 medium containing 4 mM D-glucose and 10% fetal bovine serum (FBS), previously depleted of fibronectin by passing FBS over gelatin-Sepharose (Amersham Pharmacia Biotech, Amersham, UK) (32). After serum deprivation for 24 h post log-phase cultures were treated with serum-free medium containing 4 mM D-glucose, L-[4,5-3H]Leucine (8.3 µCi · ml-1; Amersham Pharmacia Biotech), and supplemented with either rCTGF (80 ng/ml) or TGF-1 (5 ng/ml) (2 ml/well). The cultures were incubated at 37°C for 48 h, after which the media were aspirated and stored at -20°C. The cell layers were extracted sequentially with detergent solutions to obtain a deoxycholate-insoluble matrix, as described in detail previously (32). 3H-Fibronectin was immunoprecipitated from all fractions before scintillation counting in a Beckman LS6000SC counter. Protein concentration in the cell-associated fraction was determined using the BCA-200 Protein Assay Kit (Pierce, Rockford, IL).
Western Blotting
Cell layers were washed three times with PBS and then solubilized in RIPA buffer (1% vol/vol NP-40; 0.5% wt/vol sodium deoxycholate; 0.1% wt/vol SDS). Protein samples were separated by reducing SDS-PAGE on 7.5% gels and then transferred to Immobilon-P PVDF membranes (Millipore, Bedford, UK). Nonspecific sites were blocked before incubation of the membrane with primary antibody (anti-fibronectin [1/2000]; anti-EDA+ fibronectin [1/400]; anti--actin [1/3000]) overnight at 4°C. Incubation with an appropriate secondary antibody for 1 h at room temperature was followed by band visualization with enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech). SDS-PAGE molecular weight markers (Rainbow colored protein molecular weight markers, Amersham Pharmacia Biotech) were run to calibrate the gel.
Use of CTGF Antisense Oligonucleotides
CTGF phosphothioate antisense oligonucleotide or a CG matched control was added directly to cultures at a final concentration of 2 µM (according to manufacturer’s recommendation). Previous experiments have shown that this concentration leads to an appreciable decline in CTGF mRNA levels from HMC in culture (6).
FACS Analysis of Cell Surface Levels of 51 Integrin Receptor
HMC were seeded onto cell culture dishes (Corning Ltd, Corning, NY) in media containing 10% FBS previously depleted of fibronectin. Post log-phase cultures were serum-starved for 24 h before treatment with medium containing 4 mM D-glucose alone or media supplemented with either rCTGF (80 ng/ml), TGF- (5 ng/ml), or rCTGF and TGF- for different times (30 min to 72 h). Cells were then transferred to the wells of a 96-well conical-bottomed microtiter plate (Nunc International, Roskilde, Denmark). Cells were pelleted, resuspended in 100 µl of FACS buffer (HBSS containing 50 U · ml-1 penicillin, 50 µg · ml-1 streptomycin, 300 µg · ml-1 glutamine, and 2.5% FBS) containing a saturating concentration of mouse anti-human VLA-5 (51) integrin monoclonal antibody (10 µg/ml; MAB1999 Chemicon International, Inc, Temecula, CA), and incubated on ice for 30 min. After washing, the cells were incubated with goat anti-mouse IgG FITC conjugate (1/50; Dako, Glostrup, Denmark) for 30 min on ice in the dark. Washed cells were then resuspended in a total volume of 500 µl of PBS containing 1% paraformaldehyde (PFA) before analysis on a FACScan machine (Becton Dickinson, Franklin Lakes, NJ). Cells were also incubated with an isotype-matched control antibody, mouse IgG2b,
, (Sigma), or with secondary antibody alone. Data were analyzed using the CellQuest program. Relative fluorescence intensities were calculated by dividing the mean fluorescence intensity of test antibody by the mean fluorescence intensity of the appropriate isotype-matched control antibody or secondary antibody alone.
Additional experiments were undertaken, as above, for cells stimulated with either rCTGF or TGF-1 for 48 h and probed with the 1 integrin antibody 12G10 (33), using a saturating concentration of 10 µg/ml.
RT-PCR Analyses
Total RNA was isolated using RNAzol B (AMS Biotechnology, Abingdon, UK) (34). Two micrograms of each RNA sample was converted into cDNA with Superscript II RNase H- reverse transcriptase and random hexamer primers (Life Technologies BRL, Paisley, Scotland, UK). Equal amounts of cDNA were subsequently amplified by PCR. Control amplifications were performed with GAPDH to confirm the use of equal amounts of RNA. The amount of reverse transcription reaction used for the amplification (0.5 µl) was selected as being nonsaturating for the PCR product of the genes under investigation after 27 cycles of amplification. The sequences of the primers used for the amplification of integrin alpha5 mRNA were: (sense) 5'-TGCATCAACCTTAGCTTCTGCCT -3' and (antisense) 5'-ACCAGCAGGCGGCTCTGGTTCAC -3' (35). The sequences of the primers used for the amplification of integrin beta1 mRNA were: (sense) 5'-GGAAAACGGCAAATTGTCAGAAGG-3' and (antisense) 5'-TGGACCAGTGGGACACTCTGGATT-3' (35). The sequences of the primers used for the amplification of GAPDH mRNA were: (sense) 5'-ACCACAGTCCATGCCATCAC-3' and (antisense) 5'-TCCACCACCCTGTTGCTGTA-3' (32). Amplification products were electrophoresed through 1.5% (wt/vol) agarose gels and visualized by ethidium bromide staining. Bands were scanned and quantitated by densitometry using NIH Image software.
Cell Adhesion Assays
Twenty-four–well flat-bottom plates (Corning Ltd) were coated overnight at 4°C with 200 µl of a 10 µg/ml solution of fibronectin (Sigma, Poole, UK). Wells were washed with PBS and blocked with 500 µl of 10 mg/ml denatured bovine serum albumin (BSA) for 1 h at 37°C. Cell adhesion assays were performed essentially as described by Kagami et al. (31). Briefly, growth-arrested HMC were treated with media containing 4 mM D-glucose and either CTGF (80 ng/ml), TGF- (5 ng/ml), or CTGF and TGF- for 48 h. Control cultures that were maintained in serum-free media containing 4 mM D-glucose were also included. Cells were detached with trypsin, washed, and pelleted. Cells were resuspended in RPMI containing 1 mM MnCl2 and 1 mM CaCl2 at a concentration 1 x 105 cells/ml. Cells were plated onto fibronectin-coated wells (300 µl of cell suspension/well) and placed at 37°C for 50 min. Adherent cells were fixed and stained with 0.1% crystal violet. Finally, extensively washed cells were solubilized with 1% Triton X-100, and the absorbance of the solubilized cell extracts was measured at 595 nm.
For antibody blocking experiments the 5 integrin antibody BIIG2 (36) was purified from BIIG2 hybridoma cultures to ensure that a sufficient amount of antibody was available for the adhesion experiments. Cell adhesion assays were carried out as described above, the only difference being that cell suspensions were incubated with 20 µg/ml purified BIIG2 antibody (30 min, room temperature) before seeding onto fibronectin-coated tissue-culture plastic. Control suspensions, where the cells were incubated under the same conditions in the absence of BIIG2 antibody were carried out.
Immunofluorescence
HMC (passage 6 to 10) were seeded onto coverslips in medium containing 4 mM D-glucose and FBS depleted of fibronectin. Once the monolayer had reached approximately 50 to 60% confluence, the cells were serum-starved overnight and were subsequently treated with serum-free media supplemented with 4 mM D-glucose and 5 ng/ml TGF-1 or 80 ng/ml rCTGF. After 48 h, the cells were fixed and permeabilized. Nonspecific sites were then blocked. The primary antibodies (anti-human 51 [1/50] MAB1969, Chemicon; anti-human paxillin [1/100], Sigma) were incubated with the cells overnight at 4°C in a humidified chamber. Washed cells were incubated with the appropriate secondary antibody-conjugate (1/200) for 1 h at room temperature. In certain cases, incubation with the secondary antibody was followed by incubation with phalloidin-TRITC (50 µg · ml-1) for 1 h at room temperature. The coverslips were washed and mounted with Vectashield mounting medium (Vector Laboratories Inc, Burlingame, VT). The cells were inspected in a fluorescence microscope (Olympus Provis), and photographs were taken using 1600ASA Kodak color film. Control experiments, in which the primary antiserum was omitted, were also carried out.
For 51 integrin-blocking experiments, adherent cells were treated with either 10 µg/ml or 20 µg/ml 51 blocking antibody (MAB1969, Chemicon) in media containing 10% FBS depleted of fibronectin. After 48 h, the cells were processed for immunofluorescence as above, although they were not permeablized and were probed with an antibody to human fibronectin (1/500, Sigma).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
and CTGF for 48 h to examine their effects on fibronectin synthesis. 3H-Leucine was included in the culture media to label all newly synthesized protein. After treatment, the deoxycholate-insoluble extracellular matrix fraction, which was solubilized with 1% SDS and 5 mM DTT at 37°C for 30 min, was isolated from the cell layer. Immunoprecipitation of 3H-FN from the medium and all fractions of the cell layer was followed by scintillation counting to determine the effect of the two growth factors on fibronectin synthesis and insoluble fibronectin-matrix deposition. The results from two separate experiments are shown in Table 1. The addition of CTGF or TGF- to HMC cultures appreciably increased total fibronectin synthesis over basal values, during the 48-h labeling period. There was no difference between the total amount of fibronectin synthesis in cultures treated with CTGF or TGF-. Measurement of 3H-FN in the deoxycholate-insoluble fraction indicated that treatment with CTGF or TGF- led to a greater proportion of total counts being deposited in this fraction than in control cultures. The counts in both the CTGF- and TGF--treated cultures were 
60% higher than those observed in control cultures.
|
for 48 h compared with control cultures (Figure 1, A and B). The EDA+ splice variant of the molecule was also increased (Figure 1, A and B). Taken together, these data indicate that, in addition to upregulating total fibronectin synthesis by mesangial cells in culture, both CTGF and TGF- specifically promote fibronectin matrix deposition by these cells.
|
and CTGF Increase the Cell-Surface Expression of the Fibronectin Receptor, 51 Integrin, by HMC in Culture51 integrin receptor is essential for fibronectin matrix assembly (24) and is expressed by many cell types, including mesangial cells (37). TGF- and CTGF were both shown to increase fibronectin matrix deposition by mesangial cells; we therefore examined whether this was related to differences in the level of cell-surface 51 integrin receptor. Examination of the distribution of the 51 integrin receptor in HMC by immunofluorescence revealed that the receptor was widely distributed on the cell in a characteristic fibrillar adhesion pattern, which appeared to be concentrated toward the center of the cell (Figure 2A). No differences in the amount or intensity of staining were detected using this technique between control cells and cells treated with either CTGF or TGF- for up to 48 h (data not shown). The distribution of the 51 integrin receptor was compared with that observed of paxillin, a component of focal adhesions (Figure 2B). As expected, paxillin staining was observed at the ends of the actin filaments, unlike 51 integrin, the distribution of which would be expected to be closely associated with fibronectin matrix assembly sites in cells actively depositing an insoluble fibronectin matrix (38).
|
51 integrin levels. These were high on HMC maintained in 4 mM glucose medium. Moreover, exposure to either TGF- or CTGF for periods of up to 8 h had no effect on the level of 51 expressed at the cell surface (Figure 3A). However, longer treatments with TGF- or CTGF led to an increase in cell-surface 51, with TGF- having the greatest effect (Figure 3A). Levels of 51 plateaued after 48 h treatment with either growth factor, with TGF- inducing approximately a 65% increase and CTGF approximately a 25% increase over basal levels. These levels were maintained after treatment for 72 h. A typical FACS profile for cells stimulated for 48 h is shown in Figure 3B. Control experiments showed that neither an isotype-matched control antibody, mouse IgG2b,, nor the FITC-labeled secondary antibody bound HMC to any significant degree (Figure 3B). To determine whether changes in cell-surface levels of 51 were associated with changes in the subunit mRNA levels, total RNA was extracted from cells treated with either TGF- or CTGF for 48 h. Semiquantitative RT-PCR indicated that CTGF and TGF- treatment brought about significant increases in the level of mRNA for each subunit, when compared with control cultures (Figure 3, C and D). The extent of the increases was similar for both growth factors.
|
-Stimulated Increase in Mesangial Cell-Surface 51 Integrin Levels Is Partially Mediated by CTGF upregulates CTGF, and that the increase in fibronectin synthesis brought about by the addition of TGF- is mediated through the induction of CTGF (6). To determine whether the ability of TGF- to stimulate an increase in cell-surface 51 integrin in HMC was dependent on CTGF activity, cells were stimulated with TGF- (5 ng/ml) for 48 h in the presence of 2 µM phosphothioate antisense CTGF oligonucleotide. This oligonucleotide has been used previously and has been shown to downregulate CTGF mRNA levels in HMC in culture (6). Cell-surface 51 integrin levels were then determined by FACS. Figure 4 shows that the CTGF antisense significantly reduced TGF-–stimulated cell-surface 51 integrin levels. However, levels of 51 remained approximately 25% higher in the presence of antisense CTGF than in the control cultures. The control antisense oligonucleotide did not have any significant effect on TGF--stimulated 51 integrin levels. Interestingly, despite the marked inhibitory effect of antisense CTGF on TGF--stimulated 51 levels, exogenous rCTGF did not mimic exactly the effect of exogenous TGF-. It is possible that the exogenous rCTGF is not as active as CTGF produced by the cultures, and it may be more restricted in access to receptors than the latter through binding to matrix heparan sulfate proteoglycans. The apparent increase in 51 levels in cultures treated with TGF- and CTGF together over those treated with TGF- alone was not statistically significant.
|
Stimulate Mesangial Cell Adhesion to Fibronectin51 integrin levels affected HMC adhesion to the major 51 substrate, cells were seeded onto fibronectin-coated plates after stimulation with either CTGF or TGF- for 48 h. After 50 min, adherent cells were stained with crystal violet. The results are shown in Figure 5. Pretreatment with either CTGF or TGF- significantly increased the number of cells that adhered to the fibronectin-coated wells over this time, with there being no significant difference between the effect of either factor. Antisense CTGF had the effect of significantly reducing cell adhesion to fibronectin in TGF- stimulated cells, although once more levels were not reduced to those in control cultures.
|
51 integrin in mediating mesangial cell adhesion to fibronectin, we treated cells with BIIG2 (20 µg/ml), an antibody to the 5 integrin receptor that blocks cell attachment to fibronectin (36), before seeding onto fibronectin. Table 2 shows that incubation with BIIG2 significantly reduced the number of adherent cells in all cell cultures to about 30% of that seen in control cultures. Control cultures were defined as those that had been previously subjected to the same treatments, but not exposed to BIIG2. The level of inhibition did not depend on the treatment to which the cells had been previously exposed. Taken together, these data indicate that both TGF- and CTGF increase the adhesive properties of mesangial cells to fibronectin, through a mechanism partly dependent on the 51 integrin receptor. The TGF--induced effect is mediated, at least in part, via CTGF.
|
and CTGF Increase the Number of 1 Integrin Receptors in the Ligand-Occupied State1 integrin monoclonal antibody that reacts preferentially with the ligand-occupied form of 1-integrin containing heterodimers (33). FACS experiments were undertaken to determine whether the level of 12G10 binding to HMC treated with CTGF or TGF- was altered when compared with untreated control cultures. The results are shown in Figure 6. Treatment of HMC with CTGF (80 ng/ml) or TGF- (5 ng/ml) for 48 h led to a shift in the FACS profile for both growth factors when compared with the profile for untreated cells (Figure 6A). The effects of TGF- and CTGF on 12G10 binding were similar. CTGF and TGF- increased binding of 12G10 to HMC by 19% and 26%, respectively (Figure 6B). These changes were statistically significant and indicated that both CTGF and TGF- increased the level of ligand-occupied 1 integrin on the mesangial cell surface. Control experiments, where 12G10 was omitted, showed that the secondary antibody did not bind mesangial cells.
|
51 Integrin Inhibit Fibronectin Matrix Deposition by HMC In Vitro51 integrin receptor in fibronectin matrix deposition by mesangial cells in vitro. Newly adherent cells were fed with media supplemented with FBS previously depleted of fibronectin and containing antibody blocking 51 integrin (Chemicon, MAB 1969). After 48 h, the fibronectin matrix was visualized by immunofluorescence. This showed that addition of the blocking antibody to adherent cells had no effect on the number of cells that remained attached to the coverslip (data not shown). The fibronectin matrix deposited around the cells (which were non-permeablized for analysis) was visible in the form of characteristic fibrils (Figure 7A). However, the addition of the blocking antibody led to appreciably lower amounts of fibronectin matrix, which also appeared more randomly organized and less fibrillar in structure (Figure 7, B and C). Similar observations were also made with cells that were stimulated with CTGF, in that the presence of 51 integrin blocking antibody also brought about a decrease in the amount of fibronectin matrix deposited by the cells (data not shown).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
and its downstream mediator CTGF are increased in the kidney in diabetic nephropathy (3,6,17). Accumulation of extracellular matrix in the glomerular mesangium is one of the most prominent features of the disorder (1). One of the main matrix proteins deposited is fibronectin, which associates to form an insoluble matrix in a well-defined manner (24). The 51 integrin receptor is key to fibronectin-matrix formation, providing an important point of contact between the cell and extracellular fibronectin fibrils.
Previous studies have shown that expression of 51 integrin parallels mesangial content of both fibronectin and TGF- protein in renal disease (27,28,39). TGF- has also been shown to directly upregulate 51 expression by cultured rat mesangial cells (31). However, very little is known about the relationship between the levels of CTGF and 51 expression. One study showed upregulation of 5 transcripts in NRK fibroblasts (14), and CTGF levels have been shown to correlate very well with 5 levels in the ileum from patients with inflammatory bowel disease, Crohn disease, and ulcerative colitis (40). Using an HMC culture system, we sought to establish whether the ability of TGF- to stimulate 51 expression in these cells is mediated through CTGF.
In addition to upregulating total fibronectin synthesis, our results showed that TGF- and CTGF preferentially stimulate the deposition of insoluble fibronectin matrix by HMC. Western blot analyses also revealed that synthesis of the EDA+ splice variant of fibronectin is upregulated by these factors. The inclusion of the EDA segment is thought to enhance the cell-adhesive activity of fibronectin by potentiating the interaction of fibronectin with the fibronectin receptor, the 51 integrin (41). These observations led us to investigate whether the level of 51 integrin is also altered, as this is an important factor for fibronectin matrix synthesis (24–26).
Both CTGF and TGF- significantly upregulated 5 and 1 at the message level, as determined by RT-PCR. TGF- stimulated cell-surface expression of the 51 integrin in a manner very similar to that previously observed in other cell types (29,30), including rat mesangial cells (31). Treatment of the cells with CTGF also induced an increase in cell-surface 51 integrin levels, although the stimulation was less pronounced than with TGF-. However, treatment of cells with TGF- and a phosphothioate antisense oligonucleotide to CTGF specifically abrogated much of the effect of TGF-, suggesting that the effect of TGF- is mediated at least in part through the induction of CTGF. The fact that antisense CTGF does not completely abolish TGF--induced cell-surface 51 expression suggests that TGF- can act on this through more than one mechanism.
Treatment of HMC with TGF- increased their ability to adhere to fibronectin, in a manner very similar to that observed with rat mesangial cells (31). Treatment with CTGF brought about similar effects, despite the fact that cell-surface levels of 51 were much lower in these cultures. This presumably relates to CTGF treatment inducing a similar increase in ligand-occupied integrin receptor on the cell-surface as treatment with TGF-, as observed in experiments using the 12G10 antibody for detection. However, the use of blocking antibodies to the 5 integrin subunit suggested that, although 51 is the predominant receptor expressed by HMC that mediates adhesion to fibronectin, it is unlikely to be the only receptor for this.
The direct importance of the 51 integrin in fibronectin matrix assembly by HMC in culture was demonstrated by the fact that blocking antibodies to the receptor appreciably reduced matrix deposition by these cells. Soluble integrin receptors have been generated that have been shown to be functional (42,43). Specific targeting of the 51 integrin receptor could prove successful in the control of excessive fibronectin matrix production in DN, although targets further upstream in the disease cascade may prove to be better points of intervention. One such attractive target would be CTGF. The data presented in this study provide further evidence that this growth factor is a downstream mediator of many of the profibrotic actions of TGF-.
|
Acknowledgments |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
action on fibroblasts. Cytokine Growth Factor Rev 8: 171–179, 1997[CrossRef][Medline]
51) antibodies. J Cell Biol 111: 699–708, 19901 modulated the expression of 51 integrin and integrin-mediated signalling in human hepatocarcinoma cells: Biochem Biophys Res Comm 274: 519–525, 2000[CrossRef][Medline]
(TGF- ) stimulates the expression of 1 integrins and adhesion by rat mesangial cells. Exp Cell Res 229: 1–6, 1996[CrossRef][Medline]
1 integrin receptors are intricately modulated during differentiation of human cryotrophoblast to an invasive phenotype in vivo. J Clin Invest 89: 210–222, 1992
This article has been cited by other articles:
 |
|
 |
|
  P.-S. Chen, M.-Y. Wang, S.-N. Wu, J.-L. Su, C.-C. Hong, S.-E. Chuang, M.-W. Chen, K.-T. Hua, Y.-L. Wu, S.-T. Cha, et al. CTGF enhances the motility of breast cancer cells via an integrin-{alpha}vbeta3-ERK1/2-dependent S100A4-upregulated pathway J. Cell Sci., June 15, 2007; 120(12): 2053 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Okada, J. Wada, K. Hida, J. Eguchi, I. Hashimoto, M. Baba, A. Yasuhara, K. Shikata, and H. Makino Thiazolidinediones Ameliorate Diabetic Nephropathy via Cell Cycle-Dependent Mechanisms Diabetes, June 1, 2006; 55(6): 1666 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Wang, S. X. Zhang, R. Mott, R. R. Knapp, W. Cao, K. Lau, and J.-x. Ma Salutary Effect of Pigment Epithelium-Derived Factor in Diabetic Nephropathy: Evidence for Antifibrogenic Activities Diabetes, June 1, 2006; 55(6): 1678 - 1685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Shi-wen, L. A. Stanton, L. Kennedy, D. Pala, Y. Chen, S. L. Howat, E. A. Renzoni, D. E. Carter, G. Bou-Gharios, R. J. Stratton, et al. CCN2 Is Necessary for Adhesive Responses to Transforming Growth Factor-beta1 in Embryonic Fibroblasts J. Biol. Chem., April 21, 2006; 281(16): 10715 - 10726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. X. Zhang, J. J. Wang, K. Lu, R. Mott, R. Longeras, and J.-x. Ma Therapeutic Potential of Angiostatin in Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 475 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Kane, L Stevenson, C Godson, A W Stitt, and C O'Brien Gremlin gene expression in bovine retinal pericytes exposed to elevated glucose Br. J. Ophthalmol., December 1, 2005; 89(12): 1638 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. G. Ewens, R. A. George, K. Sharma, F. N. Ziyadeh, and R. S. Spielman Assessment of 115 Candidate Genes for Diabetic Nephropathy by Transmission/Disequilibrium Test Diabetes, November 1, 2005; 54(11): 3305 - 3318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baba, J. Wada, J. Eguchi, I. Hashimoto, T. Okada, A. Yasuhara, K. Shikata, Y. S. Kanwar, and H. Makino Galectin-9 Inhibits Glomerular Hypertrophy in db/db Diabetic Mice via Cell-Cycle-Dependent Mechanisms J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3222 - 3234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Qi, S. Twigg, X. Chen, T. S. Polhill, P. Poronnik, R. E. Gilbert, and C. A. Pollock Integrated actions of transforming growth factor-{beta}1 and connective tissue growth factor in renal fibrosis Am J Physiol Renal Physiol, April 1, 2005; 288(4): F800 - F809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tan, B. Wang, J.-S. Keum, and A. A. Jaffa Mechanisms through which bradykinin promotes glomerular injury in diabetes Am J Physiol Renal Physiol, March 1, 2005; 288(3): F483 - F492. [Abstract] [Full Text] [PDF] |
0.05 (total n = 9).
